Abstract: The invention relates to a recombinant cell, preferably a yeast cell comprising: a) one or more heterologous genes encoding a glycerol dehydrogenase activity; b) one or more genes encoding a dihydroxyacetone kinase (E.C. 2.7.1.28 and/or E.C. 2.7.1.29); c) one or more heterologous genes encoding a ribulose-1,5-biphosphate carboxylase oxygenase (EC 4.1.1.39, RuBisCO); and d) one or more heterologous genes encoding a phosphoribulokinase (EC 2.7.1.19, PRK); and optionally e) one or more heterologous genes encoding for a glycerol transporter. This cell can be used for the production of ethanol and advantageously produces little or no glycerol.

Abstract: The present invention relates to a rotary cylindrical mould member and a method for manufacturing a rotary cylindrical mould member for moulding food products suitable for consumption. One or more recessed mould cavities (21) are formed in an curved outer surface (22c) of at least one porous mould body (22), defining the shape of the products which are to be produced. An airflow-resistive skin layer is formed by plastic deformation of a cavity surface layer, having a first flow resistance. An inner volume of the porous mould body (22) between an inner surface (22i) and the airflow-resistive skin layer has a porous structure with a second flow resistance to a compressed air flow through the porous inner volume, wherein according to the invention the first flow resistance is essentially the same as the second flow resistance.

Abstract: The invention relates to a process for producing a fermentation product that comprises fermentation of a carbon source in a reactor with a cell, capable of converting sugar, glycerol and acetic acid, wherein the carbon source comprises sugar and acetic acid, comprising the following steps: a) Inoculating a optionally diluted carbon source with the cell; b) optionally fermenting the reactor in batch mode; c) adding carbon source comprising glycerol and optionally sugar gradually to the reactor; d) after sufficient fermentation time, isolation of fermentation product from the reactor, e) optionally keeping the remaining fraction after isolation of step d) as spent broth; and f) optionally using the spent broth in step a) to dilute the carbon source.

Abstract: The invention relates to a process for the aerobic propagation of yeast wherein the yeast is grown in a reactor, comprising the following steps: a) filling the reactor with carbon source and an initial yeast population, b) optionally growing the initial yeast population in the reactor in batch mode, c) measuring the pH in the reactor, d) adding lignocellulosic hydrolysate to the reactor in fed batch mode at a rate to set the pH in the reactor at a predetermined value, and e) after sufficient propagation, isolation of yeast from the reactor. The invention further relates to yeast propagated according to that propagation process and to a process for the production of fermentation product wherein sugar comprising hexose and pentose is anaerobically fermented to fermentation product with the propagated yeast.

Abstract: The present invention provides compounds having formula I: and pharmaceutically acceptable derivatives thereof, wherein R1-R10, q, t, X0, X1, A, B, D, E, G, J, K, L, M and Z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders associated with cellular hyperproliferation.

Abstract: The present invention provides compounds having formula (I) (and pharmaceutically acceptable derivatives thereof): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R14 and n are as defined herein.

Abstract: The present invention provides compounds having formula (1): wherein R1-R6, A, J, D, A, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors.

Abstract: The present invention provides compounds having formula (1): wherein R1-R6, A, J, D, E, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors.

Abstract: The present invention provides compounds having formula (I) (and pharmaceutically acceptable derivatives thereof): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R14 and n are as defined herein.

Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.

Abstract: The present invention provides compounds having formula I: and pharmaceutically acceptable derivatives thereof, wherein R1-R10, q, t, X0, X1, A, B, D, E, G, J, K, L, M and Z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders associated with cellular hyperproliferation.

Abstract: The present invention provides compounds having formula (I) (and pharmaceutically acceptable derivatives thereof): and additionally provides methods for the synthesis thereof and methods for the use thereof in the treatment of cancer, wherein R1-R14 and n are as defined herein.

Abstract: The present invention provides compounds haviang formula (1): wherein R1-R6, A, J, D, E, G, Q, w, x, y, and z are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors.